Entity Detail — Knowledge Graph Node
This page aggregates everything SciDEX knows about NSF: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.
NSF is a protein involved in neurodegeneration research. Key relationships include: associated with, regulates, interacts with. Associated with Als, Cancer, Glioma. Connected to 54 entities in the SciDEX knowledge graph.
No AI portrait yet
| Gene Symbol | NSF |
| Full Name | N-Ethylmaleimide Sensitive Fusion Protein |
| Chromosome | 17q21.31 |
| Function | NSF is a member of the AAA+ (ATPases Associated with diverse cellular Activities) protein family that functions as a molecular chaperone for SNARE complex recycling |
| Primary Expression | all eukaryotic cells, with high expression in neurons - Protein Complexes: Forms hexameric complexes and interacts with alpha |
| Molecular Weight | 66 kDa |
| Pathways | Apoptosis, Cell Cycle |
| UniProt ID | P46459 |
| NCBI Gene ID | 4900 |
| Ensembl ID | ENSG00000134574 |
| OMIM | 163580 |
| GeneCards | NSF |
| Human Protein Atlas | NSF |
| Associated Diseases | epilepsy |
| Known Drugs/Compounds | rapamycin |
| Interactions | AMPK, AND, LC3, MAP1LC3, MTOR, MTORC1 |
| KG Connections | 109 knowledge graph edges |
| Databases | GeneCardsHPASTRING |
Knowledge base pages for this entity
graph TD
NSF["NSF"]
Cancer{"Cancer"}
NSF -->|"regulates"| Cancer
Tumor{"Tumor"}
NSF -->|"regulates"| Tumor
Glioma{"Glioma"}
NSF -->|"regulates"| Glioma
Als{"Als"}
NSF -->|"regulates"| Als
Ms{"Ms"}
NSF -->|"regulates"| Ms
Stroke{"Stroke"}
NSF -->|"interacts with"| Stroke
LAMP1["LAMP1"]
NSF -->|"associated with"| LAMP1
ATG12["ATG12"]
NSF -->|"associated with"| ATG12
Mtor(["Mtor"])
NSF -->|"associated with"| Mtor
Autophagy(["Autophagy"])
NSF -->|"associated with"| Autophagy
GAPDH["GAPDH"]
NSF -->|"associated with"| GAPDH
STX17["STX17"]
NSF -->|"associated with"| STX17
VAMP8["VAMP8"]
VAMP8 -->|"associated with"| NSF
ULK1["ULK1"]
ULK1 -->|"associated with"| NSF
LC3["LC3"]
LC3 -->|"associated with"| NSF
MCOLN1["MCOLN1"]
MCOLN1 -->|"associated with"| NSF
GAPDH -->|"associated with"| NSF
STX17 -->|"associated with"| NSF
SQSTM1["SQSTM1"]
SQSTM1 -->|"associated with"| NSF
MAP1LC3["MAP1LC3"]
MAP1LC3 -->|"associated with"| NSF
P62["P62"]
P62 -->|"associated with"| NSF
ATG12 -->|"associated with"| NSF
STX17 -->|"contributes to"| NSF
MIRNAS["MIRNAS"]
MIRNAS -->|"regulates"| NSF
style NSF fill:#1a3a4a,stroke:#4fc3f7,stroke-width:3px,color:#e0e0e0| Target | Relation | Type | Str |
|---|---|---|---|
| SNCA | expresses | gene | 0.70 |
| Glioma | regulates | disease | 0.65 |
| Als | biomarker_for | disease | 0.65 |
| Cancer | regulates | disease | 0.65 |
| Tumor | regulates | disease | 0.65 |
| Inflammation | biomarker_for | disease | 0.65 |
| Alzheimer | biomarker_for | disease | 0.65 |
| Ms | biomarker_for | disease | 0.65 |
| Neuroinflammation | biomarker_for | disease | 0.65 |
| Als | regulates | disease | 0.65 |
| Stroke | interacts_with | disease | 0.65 |
| Ms | regulates | disease | 0.65 |
| SQSTM1 | activates | entity | 0.60 |
| STX17 | activates | entity | 0.60 |
| ULK1 | activates | entity | 0.60 |
| VAMP8 | activates | entity | 0.60 |
| cancer | activates | disease | 0.60 |
| stroke | interacts_with | disease | 0.60 |
| Apoptosis | regulates | pathway | 0.60 |
| Necroptosis | interacts_with | pathway | 0.60 |
| RIPK1 | interacts_with | gene | 0.60 |
| SQSTM1 | associated_with | gene | 0.60 |
| P62 | activates | entity | 0.60 |
| oxidative stress response | participates_in | pathway | 0.60 |
| MAP1LC3 | associated_with | gene | 0.60 |
| MTORC1 | associated_with | gene | 0.60 |
| CANCER | regulates | gene | 0.60 |
| LYSOSOME | regulates | gene | 0.60 |
| Epithelial | associated_with | cell_type | 0.60 |
| AUTOPHAGY | associated_with | gene | 0.60 |
| RNA | associated_with | gene | 0.60 |
| Raf | regulates | protein | 0.60 |
| Fus | regulates | protein | 0.60 |
| RNA | activates | gene | 0.60 |
| TRPML1 | activates | gene | 0.60 |
| autophagy pathway | participates_in | pathway | 0.60 |
| SNARE | activates | gene | 0.60 |
| Autophagy | associated_with | pathway | 0.60 |
| GAPDH | associated_with | gene | 0.60 |
| STX17 | associated_with | gene | 0.60 |
| MCOLN1 | associated_with | gene | 0.60 |
| VAMP8 | associated_with | gene | 0.60 |
| LC3 | associated_with | gene | 0.60 |
| ULK1 | associated_with | gene | 0.60 |
| Cell Cycle | regulates | pathway | 0.60 |
| RIPK1 | inhibits | gene | 0.60 |
| LAMP1 | associated_with | gene | 0.60 |
| ATG12 | associated_with | gene | 0.60 |
| Rb | regulates | protein | 0.60 |
| GENES | biomarker_for | gene | 0.60 |
| Source | Relation | Type | Str |
|---|---|---|---|
| KEAP1 | expresses | gene | 0.70 |
| AUTOPHAGY | regulates | pathway | 0.60 |
| STX17 | associated_with | gene | 0.60 |
| ATG12 | associated_with | gene | 0.60 |
| ATG12 | activates | entity | 0.60 |
| GAPDH | activates | entity | 0.60 |
| LAMP1 | activates | entity | 0.60 |
| MCOLN1 | activates | entity | 0.60 |
| LYSOSOME | regulates | gene | 0.60 |
| MTORC1 | associated_with | gene | 0.60 |
| MAP1LC3 | activates | gene | 0.60 |
| MTORC1 | activates | gene | 0.60 |
| rapamycin | targets | drug | 0.60 |
| MITOPHAGY | protects_against | pathway | 0.60 |
| MIRNAS | regulates | gene | 0.60 |
| CANCER | regulates | gene | 0.60 |
| APOPTOSIS | regulates | gene | 0.60 |
| MICRORNAS | regulates | gene | 0.60 |
| RNA | associated_with | gene | 0.60 |
| AND | regulates | gene | 0.60 |
| TRPML1 | associated_with | gene | 0.60 |
| MAP1LC3 | associated_with | gene | 0.60 |
| AUTOPHAGY | associated_with | gene | 0.60 |
| VAMP8 | associated_with | gene | 0.60 |
| ULK1 | associated_with | gene | 0.60 |
| LC3 | associated_with | gene | 0.60 |
| MCOLN1 | associated_with | gene | 0.60 |
| GAPDH | associated_with | gene | 0.60 |
| SQSTM1 | associated_with | gene | 0.60 |
| P62 | associated_with | gene | 0.60 |
| LAMP1 | associated_with | gene | 0.60 |
| LAMP1 | regulates | gene | 0.60 |
| LC3 | regulates | gene | 0.60 |
| MTOR | regulates | gene | 0.60 |
| LC3 | activates | gene | 0.60 |
| AMPK | activates | gene | 0.60 |
| AUTOPHAGY | activates | pathway | 0.60 |
| MTOR | interacts_with | gene | 0.60 |
| NECROPTOSIS | co_discussed | pathway | 0.40 |
Hypotheses where this entity is a therapeutic target
| Hypothesis | Score | Disease | Analysis |
|---|---|---|---|
| pH-Sensitive Bispecific Antibody Targeting Transferrin Recep | 0.800 | neurodegeneration | Blood-brain barrier antibody transport m |
| Magnetosonic-Triggered Transferrin Receptor Clustering | 0.719 | neurodegeneration | Blood-brain barrier transport mechanisms |
| Mitochondrial Transfer Pathway Enhancement | 0.695 | neurodegeneration | Astrocyte reactivity subtypes in neurode |
| CX43 hemichannel engineering enables size-selective mitochon | 0.686 | neurodegeneration | Mitochondrial transfer between astrocyte |
| GAP43-mediated tunneling nanotube stabilization enhances neu | 0.666 | neurodegeneration | Mitochondrial transfer between astrocyte |
| Extracellular Vesicle Cargo Transfer | 0.480 | neurodegeneration | Which specific factors in conditioned me |
| Optogenetic Control of Mitochondrial Transfer Networks | 0.476 | neurodegeneration | Mitochondrial transfer between neurons a |
| Transferrin-Alectinib Conjugation Enhances Blood-Brain Barri | 0.406 | molecular biology | Does Alectinib truly bind C1q directly w |
Scientific analyses that reference this entity
No analyses mention this entity
Experimental studies targeting or related to this entity
| Experiment | Type | Disease | Score | Feasibility | Model | Status | Est. Cost |
|---|---|---|---|---|---|---|---|
| Autophagy receptor identification for stress granule elimination | exploratory | neurodegenerative diseases | 0.900 | 0.00 | cultured cells under arsenite | proposed | N/A |
| iPSC-derived endothelial cell iron uptake with RLS CSF exposure | exploratory | restless legs syndrome | 0.900 | 0.00 | iPSC-derived human endothelial | proposed | N/A |
| Cx43 knockdown effects on mitochondrial transfer | exploratory | osteoarthritis | 0.900 | 0.00 | human bone marrow-derived MSCs | proposed | N/A |
| Confocal imaging of MSC-chondrocyte interactions during mitochondrial | exploratory | osteoarthritis | 0.850 | 0.00 | human bone marrow-derived MSCs | proposed | N/A |
| Auditory nerve responses to combined optogenetic and electrical stimul | validation | sensorineural hearing loss/dea | 0.850 | 0.00 | transgenic mice expressing ChR | proposed | N/A |
| s:** - Compare brain penetration in FcRn+/+ vs FcRn-/- mice with engin | falsification | Neuroinflammation | 0.400 | 0.50 | mouse | proposed | $200,000 |
| s:** - Compare uptake with/without magnetic particles using tight junc | falsification | Neurodegeneration | 0.400 | 0.50 | cell_line | proposed | $120,000 |
| AAV Serotype Comparison for LRRK2 Knockdown in PD Gene Therapy | validation | Parkinson's Disease | 0.400 | 0.50 | mouse | proposed | $280,000 |
| AAV Serotype Comparison for LRRK2 Knockdown in PD | validation | Parkinson's Disease | 0.400 | 0.50 | mouse | proposed | $280,000 |
| s:** - Test MCU overexpression specifically in layer II neurons in hea | falsification | Neurodegeneration | 0.400 | 0.50 | mouse | proposed | $200,000 |
| Proposed experiment from debate on Mitochondrial transfer between astr | falsification | Neurodegeneration | 0.400 | 0.50 | cell_line | proposed | $80,000 |
| Proposed experiment from debate on Mitochondrial transfer between astr | falsification | Neurodegeneration | 0.400 | 0.50 | cell_line | proposed | $100,000 |
| Mechanism: Selective Vulnerability of Dopaminergic Neurons in Parkinso | validation | Parkinson's Disease | 0.400 | 0.50 | human | proposed | $3,000,000 |
| Selective Vulnerability of Dopaminergic Neurons — Mechanism and Protec | validation | Neurodegeneration | 0.400 | 0.50 | cell_line | proposed | $160,000 |
| ER-Golgi Secretory Pathway Dysfunction in PD - Experiment Design | clinical | Parkinson's Disease | 0.400 | 0.50 | human | proposed | $7,500,000 |
| Exercise-BDNF-Mitophagy Biomarker Study in PD | clinical | Parkinson's Disease | 0.400 | 0.50 | human | proposed | $6,550,000 |
| Ferroptosis Validation in Parkinson's Disease | clinical | Parkinson's Disease | 0.400 | 0.50 | human | proposed | $6,550,000 |
| GLP-1 Agonist Neuroprotection Mechanism in PD | clinical | Parkinson's Disease | 0.400 | 0.50 | human | proposed | $6,550,000 |
| Cytochrome Therapeutics | clinical | Parkinson's Disease | 0.400 | 0.50 | human | proposed | $5,460,000 |
| AAV-LRRK2 IND-Enabling Study Design | clinical | Parkinson's Disease | 0.400 | 0.50 | human | proposed | $7,500,000 |
Scientific publications cited in analyses involving this entity
| Title & PMID | Authors | Journal | Year | Citations |
|---|---|---|---|---|
| Enhancer AAVs for targeting spinal motor neurons and descending motor pathways i [PMID:40403722] | Emily Kussick, Nelson Johansen, Naz Task | Cell Reports | 2025 | 19 |
| Organelle-specific autophagy in inflammatory diseases: a potential therapeutic t [PMID:32048886] | Yao RQ, Ren C, Xia ZF, Yao YM | Autophagy | 2021 | 2 |
| Astrocytic Connexin43 in Alzheimer's disease: mechanisms, interaction with P2 re [PMID:41062060] | Xiong W, Su Y, Verkhratsky A, Yi C | Neuropharmacology | 2026 | 1 |
| Miro1: A potential target for treating neurological disorders. [PMID:40403957] | Zeng L, Yang J, Zhang C, Zhu J, Zhong S, | Neuroscience | 2025 | 1 |
| Connexin43 hemichannel blockade turns microglia neuroprotective and mitigates co [PMID:40595567] | Su Y, Li H, Zhang W, Tao S, Wang Q, Zhan | Nat Commun | 2025 | 1 |
| Bispecific brain-penetrant antibodies for treatment of Alzheimer's disease. [PMID:40425446] | Sehlin D, Hultqvist G, Michno W, Aguilar | J Prev Alzheimers Dis | 2025 | 1 |
| Calcium-Associated Proteins in Neuroregeneration. [PMID:38397420] | Lisek M, Tomczak J, Boczek T, Zylinska L | Biomolecules | 2024 | 1 |
| Should it stay or should it go: gap junction protein GJA1/Cx43 conveys damaged l [PMID:39394955] | Domingues N, Ribeiro-Rodrigues T, Girão | Autophagy | 2024 | 1 |
| Connexin 43 regulates intercellular mitochondrial transfer from human mesenchyma [PMID:39390589] | Irwin RM, Thomas MA, Fahey MJ, Mayán MD, | Stem Cell Res Ther | 2024 | 1 |
| Mitochondria from osteolineage cells regulate myeloid cell-mediated bone resorpt [PMID:38877020] | Ding P, Gao C, Zhou J, Mei J, Li G, Liu | Nat Commun | 2024 | 1 |
| Effect of ferroptosis on chronic cerebral hypoperfusion in vascular dementia. [PMID:37709116] | Fu P, Chen Y, Wu M, Bao B, Yin X, Chen Z | Exp Neurol | 2023 | 1 |
| Selective inhibition of cannabinoid CB(1) receptor-evoked signalling by the inte [PMID:37689260] | Maroto IB, Moreno E, Costas-Insua C, Mer | Neuropharmacology | 2023 | 1 |
| lncRNA LOC100911717-targeting GAP43-mediated sympathetic remodeling after myocar [PMID:36684596] | Li P, Wang K, Yin J, Qi L, Hu H, Yang P, | Front Cardiovasc Med | 2022 | 1 |
| Machine Learning and Novel Biomarkers for the Diagnosis of Alzheimer's Disease. [PMID:33803217] | Chang CH, Lin CH, Lane HY | Int J Mol Sci | 2021 | 1 |
| Astrocyte Networks as Therapeutic Targets in Glaucomatous Neurodegeneration. [PMID:34199470] | Boal AM, Risner ML, Cooper ML, Wareham L | Cells | 2021 | 1 |
| On Iron Metabolism and Its Regulation. [PMID:33925597] | Vogt AS, Arsiwala T, Mohsen M, Vogel M, | Int J Mol Sci | 2021 | 1 |
| MIROs and DRP1 drive mitochondrial-derived vesicle biogenesis and promote qualit [PMID:34873283] | König T, Nolte H, Aaltonen MJ, Tatsuta T | Nat Cell Biol | 2021 | 1 |
| Transferrin Receptor Is a Specific Ferroptosis Marker. [PMID:32160546] | Feng H, Schorpp K, Jin J, Yozwiak CE, Ho | Cell Rep | 2020 | 1 |
| Transferrin and transferrin receptors update. [PMID:29969719] | Kawabata H | Free Radic Biol Med | 2019 | 1 |
| Miro1 regulates intercellular mitochondrial transport & enhances mesenchymal ste [PMID:24431222] | Ahmad T, Mukherjee S, Pattnaik B, Kumar | EMBO J | 2014 | 1 |
Multi-agent debates referencing this entity
No debates reference this entity
Hypotheses and analyses mentioning NSF in their description or question text
Score: 0.480 · neurodegeneration · 2026-04-25
Healthy astrocytes release EVs containing protective cargo (potentially protein or RNA) that modifies recipient motor ne
Score: 0.476 · neurodegeneration · 2026-04-02
Light-activated ion channels in astrocytes trigger calcium influx that stimulates tunneling nanotube formation and mitoc
Score: 0.406 · molecular biology · 2026-04-21
## Mechanistic Overview Transferrin-Alectinib Conjugation Enhances Blood-Brain Barrier Transport via Transferrin Recepto